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Plasma metabolomic profile varies 
with glucocorticoid dose in patients 
with congenital adrenal hyperplasia
Mohammad A. Alwashih1,3, David G. Watson1, Ruth Andrew  2, Roland H. Stimson2, Manal 
Alossaimi1,4, Gavin Blackburn5 & Brian R. Walker2
Glucocorticoid replacement therapy is the mainstay of treatment for congenital adrenal hyperplasia 
(CAH) but has a narrow therapeutic index and dose optimisation is challenging. Metabolomic profiling 
was carried out on plasma samples from 117 adults with 21-hydroxylase deficiency receiving their usual 
glucocorticoid replacement therapy who were part of the CaHASE study. Samples were profiled by using 
hydrophilic interaction chromatography with high resolution mass spectrometry. The patients were 
also profiled using nine routine clinical measures. The data were modelled by using both multivariate 
and univariate statistics by using the clinical metadata to inform the choice of patient groupings. 
Comparison of 382 metabolites amongst groups receiving different glucocorticoid doses revealed a clear 
distinction between patients receiving ≤5 mg (n = 64) and >5 mg (n = 53) daily prednisolone-equivalent 
doses. The 24 metabolites which were statistically significantly different between groups included free 
fatty acids, bile acids, and amino acid metabolites. Using 7 metabolites improved the receiver operating 
characteristic with area under the curve for predicting glucocorticoid dose of >0.9 with FDR adjusted 
P values in the range 3.3 E-04 -1.9 E-10. A combination of seven plasma metabolite biomarkers readily 
discriminates supraphysiological glucocorticoid replacement doses in patients with CAH.
Glucocorticoid replacement therapy is the mainstay of treatment for congenital adrenal hyperplasia (CAH)1 and 
both primary and secondary adrenal insufficiency2. Glucocorticoids are also employed commonly in a variety 
of inflammatory diseases such as rheumatoid arthritis, obstructive lung diseases, and asthma3. Although highly 
efficacious, treatment with glucocorticoids is generally associated with adverse effects such as obesity, hypergly-
caemia, hypertension, cardiovascular disease4 and osteoporosis5, and in children, retarded linear growth. These 
dose-related adverse effects are observed even amongst CAH patients when the goal is physiological replacement 
rather than pharmacological anti-inflammatory therapy6–8. The efficacy of glucocorticoid therapy can be assessed 
with disease-related endpoints, including adrenal androgen levels in CAH. However, given the narrow therapeu-
tic index, objective monitoring of glucocorticoid toxicity would also be valuable to assist with dose optimisation; 
unfortunately, the pharmacokinetics of oral glucocorticoids preclude maintenance of blood steroid concentra-
tions within physiological reference ranges, and no sensitive pharmacodynamic biomarkers exist with which to 
assess glucocorticoid toxicity.
Metabolomic screening has previously been applied to glucocorticoid therapy only for inflammation using 
urine biomarkers9. The aim of this study was to employ metabolomics in plasma samples which were available 
from patients with CAH1,6,10 firstly to establish whether the metabolomics profile varies across the range of gluco-
corticoid replacement regimes employed in these patients, and secondly to identify metabolites which might be 
useful for monitoring glucocorticoid toxicity.
Results
In order to examine relationships between glucocorticoid dose and metabolomic profiles, patients were grouped 
by their daily dose; (1) 1–2.5 mg, (2) >2.5–5 mg, (3) >5–7.5 mg and (4) >7.5–15 mg prednisolone equivalents 
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(Fig. 1). The metabolome profile showed substantial overlap between groups 1&2 and groups 3&4 (Fig. 1A), thus 
patient doses could not be accurately classified between groups (Table 1). However, a clear difference in metabo-
lomic profile was found between patients receiving 1–5 mg prednisolone equivalents daily (low GC, 64 patients) 
compared to patients receiving >5–15 mg (high GC, 53 patients) (Fig. 1B). The median (IQR) daily glucocorti-
coid dose was 3.75 (2.5–5) mg and 7.5 (6.25–7.5) mg for low GC and high GC groups, respectively. There were no 
statistically significant differences in any of the anthropometric and biochemical measurements between groups 
(Table 2).
The OPLS-DA model (Fig. 1B) based on 382 metabolites in 117 patients showed a clear separation between 
low GC and high GC groups with P CV-ANOVA = 7.4E-22. The metabolites which were most different between 
the two groups are shown in Table 3; the metabolites were refined based area under receiver operating character-
istic curve (AUROCC) >0.611. All the metabolites were significantly different between the two groups as judged 
by the confidence intervals obtained from the jack-knife uncertainty test available in Simca P.
The metabolites in Table 3 (24 metabolites) were then refined further by discarding metabolites which did not 
make a strong individual contribution to predicting glucocorticoid dose, based on their VIPpred versus VIPortho 
(Fig. 2), resulting in a model (Fig. 3A) based on only seven metabolites (Table 4). These 7 variables in combina-
tion produced a combined AUROCC of 0.92 (Fig. 3B). The new model (Fig. 3A) explained more of the variation 
between low GC and high GC groups (33%) compared to the earlier model (Fig. 1B) which explained only 4.3% 
Figure 1. OPLS-DA score plots showing 117 patients with CAH grouped based on their daily doses of 
glucocorticoid. (A) Patients divided into 4 groups by daily prednisolone equivalent dose: 1) patients having 
1–2.5 mg (green), 2) >2.5–5 mg (blue), 3) >5–7.5 mg (plum) and 4) >7.5–15 mg (orange). (B) Patients divided 
into 2 groups: 1) 1–5 mg (green-64 samples) and 2) >5–15 mg (blue-53 samples). The later model consists 
of one predictive x-score component; component t [1] and three orthogonal x-score components to [1–3]. t 
[1] explains 4.8% of the predictive variation in x, to[1] explains 45.7% of the orthogonal variation in x, R2X 
(cum) = 0.506, R2Y (cum) = 1, R2 (cum) = 0.829, Goodness of prediction Q2 (cum) = 0.657.
Group Samples (n) Distribution of samples
% of correctly 
classified samples AUROCC P CV-ANOVA
Comparison A 1–2.5 >2.5–5 >5–7.5 >7.5
1–2.5 18 0* 17 1 0 0.00% 0.75
2.5E-06
>2.5–5 46 0 43* 3 0 93.48% 0.89
>5–7.5 41 0 1 40* 0 97.56% 0.9
>7.5 12 0 1 11 0* 0.00% 0.81
Comparison B 1–5 >5
1–5 64 64* 0 100% 0.98
1.5E-20
>5 53 2 53* 96% 0.98
Table 1. Data corresponding to Fig. 1 regarding group assignment plus AUROCC for classification. *Number 
of samples that correctly assigned to the correct group, AUROCC = area under the ROC curve.
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of the variation. The majority of the 7 metabolites were positively correlated to glucocorticoid dose; of those, 
chenodeoxyglycocholate had the highest correlation value (r = 0.76) while N-methylnicotinamide had the lowest 
correlation value (r = 0.46).
Discussion
Using metabolomic profiling the differences between patients receiving ≤5 and >5–15 mg daily prednisolone 
equivalent doses of glucocorticoid replacement were shown. This corresponds with the daily dose of prednisolone 
which is widely regarded as ‘physiological replacement’, at 5 mg daily, suggesting that metabolic profiling is sensitive 
to supraphysiological glucocorticoid effects. By selecting individual metabolites which in combination could most 
reliably predict glucocorticoid dose, we identified seven biomarkers which in combination provide an AUROCC 
of 0.92. These metabolites may form the basis for a ‘kit’ to detect glucocorticoid toxicity. Only three of these bio-
markers were normally distributed when a QQ test was applied to the seven biomarkers. However, the OPLSDA 
model does not rely on normal distribution of markers and the jack-knife uncertainty test for significance12  
used to confirm confidence intervals is non-parametric.
The glucocorticoid dose-related biomarkers were plausibly associated with glucocorticoid action. 
Chenodeoxycholic acid is representative of bile acid biosynthesis, which is both regulated by glucocorticoids 
and may influence glucocorticoid metabolism13. Hydroxyphenylpyruvic acid can be converted to tyrosine via 
transamination, a process which is induced by glucocorticoids14. Glucocorticoids induce tryptophan dioxygenase 
(TDO)15 and might be expected to reduce levels of tryptophan and its metabolite N-methylnicotinamide but this 
is not observed in the current case. TDO has haem at its active centre and enzyme activity is regenerated by cou-
pling with the superoxide anion16, since a major source of superoxide is from xanthine oxidase, which converts 
hypoxanthine via xanthine to uric acid16, the elevated hypoxanthine and inosine in the high GC group could 
indicate inhibition of xanthine oxidase and thus possibly reduced TDO activity. Palmitoleic acid has been used as 
a plasma marker of stearoyl CoA desaturase (SCD) activity which is required for the secretion of triglycerides by 
the liver17, lower levels, and desaturation of C16:0 to C16:1, in the high GC group are consistent with glucocorti-
coid inhibition of SCD and induction of fatty liver disease18.
In a previous study aromatic amino acids levels were correlated with insulin resistance in 263 lean individuals19, 
tyrosine and phenylalanine were increased in patients receiving high GC dose. The bacterial-derived metabo-
lite 4-Hydroxy-2-oxopentanoate was also higher with insulin resistance19. In the current study this metabolite 
also increases with glucocorticoid dose. In our study C15:0, C16:0, C20:3 and C22:6 fatty acids were all elevated 
in patients receiving high GC dose while C13:0 and C16:1 fatty acids were reduced (Table 3). Similarly, ele-
vated plasma levels of C16:0, C20:3 and C22:6 were reported in patients with non-alcoholic fatty liver disease 
(NAFLD)18. In our previous study we observed that hydrocortisone increased the levels of a wide range of fatty 
acids in plasma and insulin opposed this effect20. Palmitic acid (C16:0) has a strong positive association with type 
2 diabetes, although the odd chain pentadecanoic acid (C15:0) has an inverse association with type 2 diabetes21. 
Parameter Glucocorticoid dose group Mean ± SD Q1 Median Q3 FDR-adjusted p value
Age (y)
L 36.5 ± 10.8 30.15 35 42.15
0.64
H 35.4 ± 11.7 25.6 34.85 42.25
Weight (kg)
L 75.7 ± 13.9 65.9 73 83.6
0.76
H 77.9 ± 17.4 64.4 74.6 89.63
Height (m)
L 1.56 ± 0.08 1.51 1.57 1.62
0.39
H 1.58 ± 0.08 1.52 1.58 1.64
BMI (m/kg2)
L 30.9 ± 6.04 26.9 30 33.95
0.83
H 30.84 ± 6.5 26.05 29.35 34.9
Systolic blood pressure (mmHg)
L 118.7 ± 12.1 110.16 117.33 125.8
0.27
H 122.7 ± 12.6 112.6 123 131.6
Diastolic blood pressure (mmHg)
L 73.53 ± 9.01 68 73.3 79.3
0.21
H 76.9 ± 8.8 72.6 77 81.08
UPredEqBNF
L 3.68 ± 1.3 2.5 3.75 5
1.4E-19
H 7.52 ± 1.7 6.25 7.5 7.5
USerum androstenedione
L 8.56 ± 19.1 1.475 3.35 5.85
0.42
H 11.18 ± 15.7 1.7 3.1 15
USerum 17-OH progesterone
L 65.3 ± 98.8 3 11.5 92.45
0.81
H 82.42 ± 162 4.25 12.55 80.85
Female/Male
L 45/19
H 35/18
Table 2. Comparison of anthropometric and clinical measurements between the low (L) (n = 64) and high (H) 
(n = 53) dose glucocorticoid exposed groups. All measurements were similar between the two groups except for 
glucocorticoid dose. Up-value based on Mann-Whitney U test (non-parametric), L = 1–5 mg daily prednisolone 
equivalent, H = >5–15 mg daily prednisolone equivalent, PredEqBNF = daily prednisolone equivalents of 
glucocorticoids therapies based on British National Formulary.
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Metabolites AUROCC L:H VIPpred VIPortho
Tridecanoic acid(C13:0) 0.63 1:0.9 0.58 0.54
Pentadecanoic acid(C15:0) 0.64 1:1.3 0.98 0.78
Palmitic acid*(C16:0) 0.66 1:1.4 1.06 1.07
Eicosanoic acid (C20:0) 0.65 1:1.4 1.03 0.92
Palmitoleic acid(16:1) 0.77 1:0.7 1.55 0.4
Hydroxyeicosatrienoic acid(20:3) 0.65 1:1.3 1.06 0.75
Docosahexaenoic acid(22:6) 0.65 1:1.2 0.87 0.62
Prostaglandin B1 (C20:2) 0.64 1:1.3 1.02 0.8
Inosine* 0.63 1:0.9 0.69 0.56
Uridine* 0.75 1:0.7 1.21 0.64
Hypoxanthine* 0.73 1:2.4 2.11 1.02
Methionine* 0.73 1:1.2 0.87 0.4
5-L-Glutamyl-taurine 0.65 1:1.6 1.14 0.85
Tryptophan* 0.67 1:1.7 1.59 0.97
Dehydroquinate 0.67 1:1.3 1.02 0.82
3(4-Hydroxyphenyl)pyruvate* 0.75 1:0.5 1.8 0.6
Alpha-N-Phenylacetyl-L-glutamine 0.61 1:0.9 0.55 0.43
4-Hydroxy-2-oxopentanoate 0.65 1:3.5 2.34 1.6
Asparagine* 0.72 1:2.6 2.29 1.14
Threonine* 0.62 1:0.7 1.14 0.56
Keto-glutaramic acid 0.64 1:0.8 0.8 0.65
N-Methylnicotinamide 0.69 1:2.2 1.85 0.85
Octanoylcarnitine 0.66 1:1.4 1.16 0.83
Chenodeoxyglycocholic acid 0.82 1:4.8 6.73 1.46
Table 3. Putative biomarkers significantly different between the low (L) and high (H) glucocorticoid dose 
groups. *Retention time matches standard, AUROCC = area under the ROC curve, VIPpred = predictive value 
of variable importance in the projection, VIPortho = orthogonal value of variable importance in the projection. 
VIP values represent the contribution of the metabolite in the variability between the two groups compared to 
the other metabolites.
Figure 2. Bars plot shows 24 metabolites (Table 3). Each bar represents a metabolite on y-axis its AUROCC 
value on the x-axis. Each metabolite bar comprises of two segments; VIPpred (predictive value of variable 
importance in the projection) (blue) and VIPortho (orthogonal value of variable importance in the projection) 
(red), their values presented as percentages. A metabolite was included in the final model if it had VIPpred 
≥2*VIPortho. Only seven metabolites passed the filter.
www.nature.com/scientificreports/
5Scientific RePoRTS | 7: 17092  | DOI:10.1038/s41598-017-17220-5
Urinary excretion of N-methylnicotinamide (NMN), a metabolite of tryptophan which is increased with high GC 
dose in the current study, has been found to be elevated in type 2 diabetes along with its metabolites the N-methyl 
pyridine carboxamides, and knock down of nicotinamide N-methyl transferase protects against obesity22. 
Patients with impaired glucose tolerance (IGT) have reduced levels of phenylacetyl-glutamine and increased 
levels of acylcarnitines and α-ketoglutarate, a pattern indicative of TCA cycle intermediate depletion which inter-
feres with insulin action23, as well as reduced tryptophan, xanthine, methionine and nucleotides; patients with 
diabetes also have a higher plasma level of octanoylcarnitine compared to non-diabetic individuals24. We found 
these diabetes-related metabolites to be altered with glucocorticoid dose (Table 3).
This observational study cannot distinguish metabolites which are directly affected by glucocorticoids from 
those which are indirectly affected, for example by the documented differences in body composition with varia-
tion in glucocorticoid dose, or by differences in efficacy of suppression of adrenal androgens1,10. In addition in this 
large observational study it was not possible to control diet. However, this does not detract from the potential util-
ity of these markers, which are substantially more sensitive than the non-specific clinical indicators presently in 
use, listed in Table 2. All the 7 candidate biomarkers had AUROC curve values above 0.7 and a high contribution 
to the separation between the high GC and low GC groups and low within-group variability. Although the current 
study is limited by use of a single analytical platform, the markers discovered could be used as reliable predictors 
Figure 3. (A) OPLS-DA score plot was comprised 7 putative biomarkers (Table 4) quantified in 117 patients. 
Green observations (64 samples) represent patients receiving a GC dose of 1–5 prednisolone equivalent and 
the blue observations (53 samples) represent patients receiving GC dose >5–15 mg prednisolone equivalent. 
The model consists of one predictive x-score components; component t[1] and one orthogonal x-score 
component to[1]. t[1] explains 33.7% of the predictive variation in x, to[1] explains 23% of the orthogonal 
variation in x, R2X (cum) = 0.57, R2Y (cum) = 1, R2 (cum) = 0.535, Goodness of prediction Q2 (cum) = 0.497. 
Plot (B) showing area under the ROC curve (AUC) of the two groups, x-axis showing (FPR) false positive rate 
(1-specificity), y-axis showing true positive rate (sensitivity). AUC for 1) 1–5 = 0.92 and 2) >5–15 = 0.92.
Putative biomarker FDR-adjusted p value L:H VIP pred VIP orth r 99% CI
Asparagine* 4.5E-05 1:2.6 2.29 1.14 0.52 (0.08, 0.34)
Tryptophan* NA 1:1.6 1.59 0.79 0.53 (0.12, 0.29)
4-Hydroxyphenyl pyruvate* 6.6E-05 1:0.5 1.8 0.6 −0.57 (−0.37, −0.08)
Palmitoleic acid NA 1:0.7 1.55 0.4 −0.66 (−0.42, −0.1)
Chenodeoxyglycocholate NA 1:4.8 6.73 1.46 0.76 (0.16, 0.44)
N-Methylnicotinamide NA 1:2.2 1.85 0.85 0.46 (0.02, 0.34)
Hypoxanthine* 1.8E-05 1:2.4 2.11 1.02 0.51 (0.05, 0.34)
Table 4. List of significant biomarkers used to build the OPLS-DA model in Fig. 2. *Retention time matches 
standard. r = correlation coefficient of a metabolite to high dose of GC. NA The metabolite is not normally 
distributed.
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of supraphysiological GC dose and incorporated into a rapid targeted screen. This is something we will now 
address in a quantitative manner. There is some commonality between the marker metabolites reported here and 
those reported in our earlier study20. In our previous study increasing the dose of hydrocortisone used increased 
the levels of docosahexanoic acid, eicosanoic acid (C20:0) and hypoxanthine as observed in the current study. The 
two studies are not entirely comparable since in the previous study a high and a low dose of corticosteroid was 
used rather than a gradation of doses as in the current case. What is absent in the current case is a clear effect on 
branched chain amino acids which in the previous study were elevated by increased HC dose. These metabolites 
are also established markers of a pre-diabetic state25 but are not highlighted as important markers in the current 
study. The value of a multivariate statistical approach is confirmed in the current study, particularly since the 
metabolite markers are not normally distributed, and the final OPLSDA model is very strong considering that the 
seven biomarkers can be used to largely distinguish between the two groups in this large co-hort.
Materials and Methods
Experimental details for sample preparation and analysis are given in supplementary material along with details 
for data extraction and metabolite identification.
Patient recruitment. The UK Congenital adrenal Hyperplasia Adult Study Executive (CaHASE) cohort is 
a cross-sectional study of adult CAH patients (aged ≥18 years) recruited from 17 specialized endocrine centres 
across the UK. The study protocol was approved by West Midlands research ethics committee (MREC/03/7/086) 
and registered with ClinicalTrials.gov (NCT00749593) and has been previously published in detail10. All partic-
ipants gave written informed consent. All methods were performed in accordance with the relevant guidelines 
determined by the protocols approved by the ethics committee. This study was not a clinical trial but was an 
observational clinical study and therefore is not categorised as a clinical trial and is not registrable as one.
Clinical Procedures. Participants attended the research unit of their respective centre after an overnight 
fast having taken their regular medication, followed by medical history, physical examination (height, weight, 
blood pressure) and blood sampling (including for 17-hydroxyprogesterone (17OHP), androstenedione). All 
laboratories participate in the UK NEQAS scheme for quality control of steroid assays. Inclusion criteria for the 
metabolomics analysis were as follows: known 21-hydroxylase deficiency; additional serum sample collected at 
time of recruitment; full anthropometric and biochemical data available for each participant. Samples from 117 
patients were used for metabolomics analysis; subjects were treated with hydrocortisone, prednisolone and dex-
amethasone or combination therapy. Glucocorticoid therapies were converted to daily prednisolone equivalents 
based on the relative potencies of the steroids reported in the British National Formulary (PredEqBNF)26.
Statistical Analysis. The methods used for statistical analysis are described in supplementary material and 
also in our previous publication20.
Data Availability Statement. The datasets generated during and/or analysed during the current study are 
available from the corresponding author on reasonable request.
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